Blood Cell Patterns Predict Venetoclax Response
Erythroid Proliferation in MDS: A Distinct Subtype with Poorer Response to Standard Therapy
Table of Contents
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematologic malignancies characterized by ineffective hematopoiesis and a risk of change to acute myeloid leukemia (AML). Recent research highlights the clinical and molecular distinctions of a subtype defined by erythroid proliferation (EP MDS), revealing poorer outcomes with hypomethylating agent (HMA)-venetoclax therapy and suggesting a need for alternative treatment strategies.
Understanding Erythroid Proliferation in MDS
Traditionally, MDS classification has focused on blast percentage and cytogenetic abnormalities. However, emerging evidence points to the importance of considering the degree of erythroid involvement. EP MDS is characterized by a disproportionately high percentage of erythroid progenitors in the bone marrow. This isn’t simply an increase in red blood cell production; it’s a dysfunctional proliferation that contributes to ineffective hematopoiesis and disease progression.
Identifying EP MDS is crucial because it demonstrates a unique molecular landscape and clinical behavior compared to non-EP MDS. While the exact prevalence varies, studies estimate EP MDS comprises approximately 18% of all MDS cases. This distinction is typically made through bone marrow examination, assessing the percentage of erythroid cells and their morphology.
Poorer Outcomes with HMA-Venetoclax in EP MDS
A recent study published in Leukemia led by researchers at The University of Texas MD Anderson Cancer Center, sheds light on the challenges of treating EP MDS with standard therapies. The study found that patients with EP MDS treated with hypomethylating agents (HMAs) in combination with venetoclax experienced considerably higher rates of leukemic transformation (32% vs 12%; P = .040) and demonstrably worse overall survival (8.3 months vs not reached; P = .041) compared to those without this erythroid proliferation.
Venetoclax, a BCL-2 inhibitor, has shown promise in treating MDS, notably when combined with HMAs. However, the study suggests that EP MDS patients may not benefit as much from this combination. This finding underscores the need to identify EP MDS and possibly explore alternative therapeutic approaches.
The Role of BCL-XL and BCL-2
Immunohistochemical analysis revealed a key difference between EP and non-EP MDS: significantly higher expression of BCL-XL in EP cases (62.5% vs 10%; P = .013). BCL-XL is an anti-apoptotic protein that can protect leukemic cells from programmed cell death, potentially contributing to treatment resistance. Interestingly, BCL-2 expression was lower in EP cases (5% vs 30%; P = .052), suggesting that venetoclax, which targets BCL-2, might potentially be less effective in this subtype.
These findings suggest that BCL-XL might potentially be a critical survival factor in EP MDS, and inhibiting BCL-XL could be a promising therapeutic strategy. Further research is needed to confirm this hypothesis and develop effective BCL-XL inhibitors for this patient population.
Implications for Treatment and Future Research
The study’s authors emphasize the importance of recognizing EP MDS as a distinct entity and dynamically assessing erythroid populations in MDS patients. The research supports the development of alternative therapeutic strategies, particularly those targeting BCL-XL, for high-risk EP MDS cases.
Several key areas require further investigation:
Genomic Subgroups: While EP MDS demonstrates distinct genomic subsets, further research is needed to definitively identify these subgroups and understand how they influence clinical behavior.
Functional Validation: The increased BCL-XL expression needs to be validated in larger studies, and functional studies are crucial to determine if this translates into BCL-XL dependence.
TP53 Mutation Impact: Given the high incidence of TP53 mutations in EP MDS, studies are needed to determine if poor outcomes with venetoclax-based therapy are driven by TP53 mutations or the erythroid differentiation bias.
Clinical Trials: Clinical trials evaluating the activity of BCL-XL inhibitors in EP MDS patients are urgently needed.
This research, led by Alexandre Bazinet, MD, Sanam loghavi, MD, and Guillermo Montalban-Bravo, MD, at MD Anderson Cancer Center, represents a significant step forward in understanding the complexities of MDS and tailoring treatment strategies to individual patient characteristics. A more nuanced approach to MDS classification and treatment, incorporating erythroid proliferation status, promises to improve outcomes for patients with this challenging disease.